about
Excitatory amino acid antagonists for acute strokeCerebral small vessel disease: Capillary pathways to stroke and cognitive declineBrain repair: cell therapy in strokeSystematic review of methods for assessing leptomeningeal collateral flowEvaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project membersGlutamate-based therapeutic approaches: clinical trials with NMDA antagonistsThrombolytic therapy for stroke: a review with particular reference to elderly patients.What constitutes a true hyperdense middle cerebral artery sign?Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale.Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview.Diffusion-weighted imaging and diagnosis of transient ischemic attack.Magnesium in stroke treatment.Why have neuro-protectants failed?: lessons learned from stroke trials.Is inadequate family history a barrier to diagnosis in CADASIL?Inflammation and ischaemic stroke.Multi-center prediction of hemorrhagic transformation in acute ischemic stroke using permeability imaging featuresClinical relevance and practical implications of trials of perfusion and angiographic imaging in patients with acute ischaemic stroke: a multicentre cohort imaging studyHyperglycemia accelerates apparent diffusion coefficient-defined lesion growth after focal cerebral ischemia in rats with and without features of metabolic syndrome.Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial.Do iodinated contrast agents impair fibrinolysis in acute stroke? A systematic review.Stem cells in stroke treatment: the promise and the challenges.INTERACT-2: should blood pressure be aggressively lowered acutely after intracerebral hemorrhage?STICH 2: does decompression have a role in superficial intracerebral hematoma?Changing clinical patterns and increasing prevalence in CADASIL.Advances in neuroimaging.Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.Clinical trial design for stem cell therapies in stroke: What have we learned?Stem cell therapy in stroke: designing clinical trials.Atherosclerotic Carotid Plaque Composition: A 3T and 7T MRI-Histology Correlation Study.What is the relationship among penumbra volume, collaterals, and time since onset in the first 6 h after acute ischemic stroke?Imaging of acute stroke and transient ischaemic attack.Detection of ischemic penumbra using combined perfusion and T2* oxygen challenge imaging.Stroke penumbra defined by an MRI-based oxygen challenge technique: 1. Validation using [14C]2-deoxyglucose autoradiography.Intracranial delivery of stem cells.Iodinated contrast media and cerebral hemorrhage after intravenous thrombolysis.The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism.T2*-weighted magnetic resonance imaging with hyperoxia in acute ischemic stroke.Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial.Early carotid endarterectomy following thrombolysis in the hyperacute treatment of stroke.Insular cortex hypoperfusion and acute phase blood glucose after stroke: a CT perfusion study.
P50
Q24248015-CC514411-E25B-4673-876B-E8573DC2DA4BQ26776375-F006C80F-2774-4699-8588-F5855D00C1A0Q26866330-D1CAF1DB-B4DF-4925-A8AC-052E1411219DQ27023224-DCB8B5D5-EAC6-4475-9104-FCB366C5BC57Q28175021-45BEB02C-D29C-45D0-95D7-096B163BB863Q28287381-1439B96C-29CF-4944-A15A-3E26C849FC98Q33873285-0745B3F0-389D-42C5-B008-306228019BADQ33924680-4F436AAC-FE19-410B-8A19-7981CDAB66E9Q34148131-5F5DF142-B2FD-4EA4-819D-BB63DFB52AABQ34395655-227F5785-49C1-4CDE-A7E5-9D9C68139403Q34470583-13AEB6F6-0F89-4099-86F4-772A779DD2DEQ35032195-9835AD4C-EFF3-44B0-A487-ECAAE6B2D7DFQ36245471-537436B2-761E-433C-8CF5-42EDCA625B61Q36283775-67EE2E82-8DE6-45BB-9874-4CD5F48AF29CQ36818682-D57A8768-15CD-4FD8-96C8-CE5A0E116DFAQ36913282-A8E48715-016A-4EEF-9DD2-B9C5D9DF1939Q37129984-1AFFFD90-5C03-4B4B-A4EA-BC054F927CF6Q37216100-A481C2C1-F19D-4724-B57B-E1495C66B180Q37222956-59097F85-ACDF-457D-AC90-164C09DD5E37Q37596207-187C71CA-74F3-4E37-99E7-21C9D952C524Q38019968-2BF95973-741D-4AC9-B02A-762F9ACD2BC9Q38132530-994E0D4C-0015-4B0A-8E0A-91A3CA9B4E8FQ38136301-437CE6F8-C1E0-4461-B5DA-D21217382BB0Q38212785-602636CD-3C6B-4788-9AA2-1BABF78877BEQ38253413-EEE27710-4FAF-43E9-9612-CDF98CD8B826Q38401222-5AA08C50-3528-40E9-B7B5-18D50B7BC235Q38821780-4108B7AB-7700-42A6-BA29-D6447F5AD4E2Q39567641-48C840A3-13DB-4B7D-9471-36AA733CCD21Q39965885-A88501BD-D7D9-466F-9777-0D0CE510F6D0Q40110982-B78F4905-40D3-4367-BE33-263A7C324B91Q42011267-6E8DD7CA-AD67-4950-B536-0305866D9612Q42108004-B246CC06-8873-4FA1-9AE3-EFAAA3E7EA4DQ42270352-DC5C0C9B-76D0-4DA7-AF70-EA4F34CD42E8Q44193661-34F08FF2-3896-41D4-A245-7E70549A07CCQ45805306-84D902FF-C81F-4554-B183-722F3FE45E2AQ46626668-BD67E0D5-B192-41FF-BACF-AF68C3F0BF06Q48150582-073433B5-15F0-4D62-9AE9-23B413D7A1EBQ48249416-F6731161-2242-470A-94D4-05F1F469DD32Q48318459-3B314A57-31F8-444D-AE7F-0E9956D7FCDAQ48325490-40BF1388-EE97-49A5-8137-989C8A057485
P50
description
researcher
@en
wetenschapper
@nl
name
K W Muir
@en
K W Muir
@nl
type
label
K W Muir
@en
K W Muir
@nl
prefLabel
K W Muir
@en
K W Muir
@nl
P106
P31
P496
0000-0001-9535-022X